J&J Stops Making Drug-Coated Heart Stents Amid Falling Sales
This article is for subscribers only.
Johnson & Johnson plans to leave the market for the drug-coated heart stents it pioneered, in a restructuring that will close two factories and cut as many as 1,000 jobs.
The manufacture of Cypher and Cypher Select Plus stents and development of a new model will end this year, the New Brunswick, New Jersey-based company said in a statement today. Boston Scientific Corp., the current stent market leader, rose 2.8 percent in New York trading.